Elevated soluble CD23 level indicates increased risk of B cell non-Hodgkin’s lymphomas: evidence from a meta-analysis
The aim of the present study was to determine whether circulating soluble CD23 (sCD23) was associated with B cells non-Hodgkin’s lymphomas (B-NHL). PubMed, EMBASE, and ISI Web of Science were extensively searched without language restriction. Data was extracted in a standardized data collection shee...
Gespeichert in:
| Veröffentlicht in: | Annals of hematology 2018-08, Vol.97 (8), p.1317-1325 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1325 |
|---|---|
| container_issue | 8 |
| container_start_page | 1317 |
| container_title | Annals of hematology |
| container_volume | 97 |
| creator | Huang, Yi-shu Zhou, Xiang Yang, Zhi-fang Lv, Zheng-tao |
| description | The aim of the present study was to determine whether circulating soluble CD23 (sCD23) was associated with B cells non-Hodgkin’s lymphomas (B-NHL). PubMed, EMBASE, and ISI Web of Science were extensively searched without language restriction. Data was extracted in a standardized data collection sheet after two reviewers scanned studies independently. The association between sCD23 and NHL was indicated as odds ratio (OR) along with its related 95% confidence interval (95% CI). Meta-analysis was conducted via RevMan 5.3. A total of five studies, which included 964 B-NHL patients and 1243 matched controls without B-NHL, among which 257 were HIV-positive donors and 986 were general controls, were included in our study. Meta-analysis revealed a significant association between peripheral sCD23 level and B-NHL in HIV-positive samples (OR 1.66, 95% CI 1.25, 2.20;
P
= 0.0005) as well as the general population (OR 2.51; 95% CI 1.71, 3.86;
P
|
| doi_str_mv | 10.1007/s00277-018-3349-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2038270755</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2036910520</sourcerecordid><originalsourceid>FETCH-LOGICAL-c324t-1fa88869d9ea0c03203e5f6e383f2ea8298d09c8b2fce22d1913be94a7aad59b3</originalsourceid><addsrcrecordid>eNp1kcFu1DAQhi0EosvCA3BBlrhwMYztZGNzg6VQpEpc4Gw5zqSkdeLFsynKjdfo6_VJ8LIFJCR8Gcvzze-RPsaeSngpAZpXBKCaRoA0QuvKiuUeW8lKKwG1qe6zFVhtRV3OCXtEdAkglanUQ3aibFODlpsV-34a8drvseOU4txG5Nt3SvPyiJEPUzeE0qRyCxk9FSwPdMVTz9_ygDHyKU3iLHUXV8N0--OGeFzG3dc0enrN8XrocArI-5xG7vmIey_85ONCAz1mD3ofCZ_c1TX78v708_ZMnH_68HH75lwEraq9kL03xmxsZ9FDAK1AY91vUBvdK_RGWdOBDaZVfUClOmmlbtFWvvG-q22r1-zFMXeX07cZae_GgQ6b-wnTTK4EGtVAU9cFff4PepnmXPb9RW2shLrUNZNHKuRElLF3uzyMPi9OgjtYcUcrrlhxBytuKTPP7pLndsTuz8RvDQVQR4BKa7rA_Pfr_6f-BD6gmRg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2036910520</pqid></control><display><type>article</type><title>Elevated soluble CD23 level indicates increased risk of B cell non-Hodgkin’s lymphomas: evidence from a meta-analysis</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Huang, Yi-shu ; Zhou, Xiang ; Yang, Zhi-fang ; Lv, Zheng-tao</creator><creatorcontrib>Huang, Yi-shu ; Zhou, Xiang ; Yang, Zhi-fang ; Lv, Zheng-tao</creatorcontrib><description>The aim of the present study was to determine whether circulating soluble CD23 (sCD23) was associated with B cells non-Hodgkin’s lymphomas (B-NHL). PubMed, EMBASE, and ISI Web of Science were extensively searched without language restriction. Data was extracted in a standardized data collection sheet after two reviewers scanned studies independently. The association between sCD23 and NHL was indicated as odds ratio (OR) along with its related 95% confidence interval (95% CI). Meta-analysis was conducted via RevMan 5.3. A total of five studies, which included 964 B-NHL patients and 1243 matched controls without B-NHL, among which 257 were HIV-positive donors and 986 were general controls, were included in our study. Meta-analysis revealed a significant association between peripheral sCD23 level and B-NHL in HIV-positive samples (OR 1.66, 95% CI 1.25, 2.20;
P
= 0.0005) as well as the general population (OR 2.51; 95% CI 1.71, 3.86;
P
< 0.00001). Meta-analysis, stratified by sampling time prior to diagnosis, indicated potential HIV-NHL patients are 2.34-folds more likely to have higher blood sCD23 level, although this association is statistically meaningful only during 3–5 years prior to diagnosis (95% CI 1.27, 4.33). Subgroup analysis based on B-NHL type demonstrated a significant association between sCD23 level and diffuse large B cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), and follicular lymphoma (FL). The findings of our study indicate a positive association of circulating sCD23 level and B-NHL risks and highlight the possibility of sCD23 as a predictive marker of B-NHL. However, to better understand the underlying mechanism, further studies are needed.</description><identifier>ISSN: 0939-5555</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s00277-018-3349-y</identifier><identifier>PMID: 29750316</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Female ; Hematology ; HIV ; HIV Infections - blood ; HIV-1 ; Human immunodeficiency virus ; Humans ; Lymphoma ; Lymphoma, B-Cell - blood ; Male ; Medicine ; Medicine & Public Health ; Meta-analysis ; Neoplasm Proteins - blood ; Oncology ; Receptors, IgE - blood ; Review Article ; Risk Factors ; Studies</subject><ispartof>Annals of hematology, 2018-08, Vol.97 (8), p.1317-1325</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2018</rights><rights>Annals of Hematology is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c324t-1fa88869d9ea0c03203e5f6e383f2ea8298d09c8b2fce22d1913be94a7aad59b3</cites><orcidid>0000-0002-8238-7194</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00277-018-3349-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00277-018-3349-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29750316$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Huang, Yi-shu</creatorcontrib><creatorcontrib>Zhou, Xiang</creatorcontrib><creatorcontrib>Yang, Zhi-fang</creatorcontrib><creatorcontrib>Lv, Zheng-tao</creatorcontrib><title>Elevated soluble CD23 level indicates increased risk of B cell non-Hodgkin’s lymphomas: evidence from a meta-analysis</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><addtitle>Ann Hematol</addtitle><description>The aim of the present study was to determine whether circulating soluble CD23 (sCD23) was associated with B cells non-Hodgkin’s lymphomas (B-NHL). PubMed, EMBASE, and ISI Web of Science were extensively searched without language restriction. Data was extracted in a standardized data collection sheet after two reviewers scanned studies independently. The association between sCD23 and NHL was indicated as odds ratio (OR) along with its related 95% confidence interval (95% CI). Meta-analysis was conducted via RevMan 5.3. A total of five studies, which included 964 B-NHL patients and 1243 matched controls without B-NHL, among which 257 were HIV-positive donors and 986 were general controls, were included in our study. Meta-analysis revealed a significant association between peripheral sCD23 level and B-NHL in HIV-positive samples (OR 1.66, 95% CI 1.25, 2.20;
P
= 0.0005) as well as the general population (OR 2.51; 95% CI 1.71, 3.86;
P
< 0.00001). Meta-analysis, stratified by sampling time prior to diagnosis, indicated potential HIV-NHL patients are 2.34-folds more likely to have higher blood sCD23 level, although this association is statistically meaningful only during 3–5 years prior to diagnosis (95% CI 1.27, 4.33). Subgroup analysis based on B-NHL type demonstrated a significant association between sCD23 level and diffuse large B cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), and follicular lymphoma (FL). The findings of our study indicate a positive association of circulating sCD23 level and B-NHL risks and highlight the possibility of sCD23 as a predictive marker of B-NHL. However, to better understand the underlying mechanism, further studies are needed.</description><subject>Female</subject><subject>Hematology</subject><subject>HIV</subject><subject>HIV Infections - blood</subject><subject>HIV-1</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Lymphoma</subject><subject>Lymphoma, B-Cell - blood</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Meta-analysis</subject><subject>Neoplasm Proteins - blood</subject><subject>Oncology</subject><subject>Receptors, IgE - blood</subject><subject>Review Article</subject><subject>Risk Factors</subject><subject>Studies</subject><issn>0939-5555</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kcFu1DAQhi0EosvCA3BBlrhwMYztZGNzg6VQpEpc4Gw5zqSkdeLFsynKjdfo6_VJ8LIFJCR8Gcvzze-RPsaeSngpAZpXBKCaRoA0QuvKiuUeW8lKKwG1qe6zFVhtRV3OCXtEdAkglanUQ3aibFODlpsV-34a8drvseOU4txG5Nt3SvPyiJEPUzeE0qRyCxk9FSwPdMVTz9_ygDHyKU3iLHUXV8N0--OGeFzG3dc0enrN8XrocArI-5xG7vmIey_85ONCAz1mD3ofCZ_c1TX78v708_ZMnH_68HH75lwEraq9kL03xmxsZ9FDAK1AY91vUBvdK_RGWdOBDaZVfUClOmmlbtFWvvG-q22r1-zFMXeX07cZae_GgQ6b-wnTTK4EGtVAU9cFff4PepnmXPb9RW2shLrUNZNHKuRElLF3uzyMPi9OgjtYcUcrrlhxBytuKTPP7pLndsTuz8RvDQVQR4BKa7rA_Pfr_6f-BD6gmRg</recordid><startdate>20180801</startdate><enddate>20180801</enddate><creator>Huang, Yi-shu</creator><creator>Zhou, Xiang</creator><creator>Yang, Zhi-fang</creator><creator>Lv, Zheng-tao</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8238-7194</orcidid></search><sort><creationdate>20180801</creationdate><title>Elevated soluble CD23 level indicates increased risk of B cell non-Hodgkin’s lymphomas: evidence from a meta-analysis</title><author>Huang, Yi-shu ; Zhou, Xiang ; Yang, Zhi-fang ; Lv, Zheng-tao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c324t-1fa88869d9ea0c03203e5f6e383f2ea8298d09c8b2fce22d1913be94a7aad59b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Female</topic><topic>Hematology</topic><topic>HIV</topic><topic>HIV Infections - blood</topic><topic>HIV-1</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Lymphoma</topic><topic>Lymphoma, B-Cell - blood</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Meta-analysis</topic><topic>Neoplasm Proteins - blood</topic><topic>Oncology</topic><topic>Receptors, IgE - blood</topic><topic>Review Article</topic><topic>Risk Factors</topic><topic>Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Huang, Yi-shu</creatorcontrib><creatorcontrib>Zhou, Xiang</creatorcontrib><creatorcontrib>Yang, Zhi-fang</creatorcontrib><creatorcontrib>Lv, Zheng-tao</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huang, Yi-shu</au><au>Zhou, Xiang</au><au>Yang, Zhi-fang</au><au>Lv, Zheng-tao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Elevated soluble CD23 level indicates increased risk of B cell non-Hodgkin’s lymphomas: evidence from a meta-analysis</atitle><jtitle>Annals of hematology</jtitle><stitle>Ann Hematol</stitle><addtitle>Ann Hematol</addtitle><date>2018-08-01</date><risdate>2018</risdate><volume>97</volume><issue>8</issue><spage>1317</spage><epage>1325</epage><pages>1317-1325</pages><issn>0939-5555</issn><eissn>1432-0584</eissn><abstract>The aim of the present study was to determine whether circulating soluble CD23 (sCD23) was associated with B cells non-Hodgkin’s lymphomas (B-NHL). PubMed, EMBASE, and ISI Web of Science were extensively searched without language restriction. Data was extracted in a standardized data collection sheet after two reviewers scanned studies independently. The association between sCD23 and NHL was indicated as odds ratio (OR) along with its related 95% confidence interval (95% CI). Meta-analysis was conducted via RevMan 5.3. A total of five studies, which included 964 B-NHL patients and 1243 matched controls without B-NHL, among which 257 were HIV-positive donors and 986 were general controls, were included in our study. Meta-analysis revealed a significant association between peripheral sCD23 level and B-NHL in HIV-positive samples (OR 1.66, 95% CI 1.25, 2.20;
P
= 0.0005) as well as the general population (OR 2.51; 95% CI 1.71, 3.86;
P
< 0.00001). Meta-analysis, stratified by sampling time prior to diagnosis, indicated potential HIV-NHL patients are 2.34-folds more likely to have higher blood sCD23 level, although this association is statistically meaningful only during 3–5 years prior to diagnosis (95% CI 1.27, 4.33). Subgroup analysis based on B-NHL type demonstrated a significant association between sCD23 level and diffuse large B cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), and follicular lymphoma (FL). The findings of our study indicate a positive association of circulating sCD23 level and B-NHL risks and highlight the possibility of sCD23 as a predictive marker of B-NHL. However, to better understand the underlying mechanism, further studies are needed.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>29750316</pmid><doi>10.1007/s00277-018-3349-y</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-8238-7194</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-5555 |
| ispartof | Annals of hematology, 2018-08, Vol.97 (8), p.1317-1325 |
| issn | 0939-5555 1432-0584 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2038270755 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Female Hematology HIV HIV Infections - blood HIV-1 Human immunodeficiency virus Humans Lymphoma Lymphoma, B-Cell - blood Male Medicine Medicine & Public Health Meta-analysis Neoplasm Proteins - blood Oncology Receptors, IgE - blood Review Article Risk Factors Studies |
| title | Elevated soluble CD23 level indicates increased risk of B cell non-Hodgkin’s lymphomas: evidence from a meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T02%3A18%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Elevated%20soluble%20CD23%20level%20indicates%20increased%20risk%20of%20B%20cell%20non-Hodgkin%E2%80%99s%20lymphomas:%20evidence%20from%20a%20meta-analysis&rft.jtitle=Annals%20of%20hematology&rft.au=Huang,%20Yi-shu&rft.date=2018-08-01&rft.volume=97&rft.issue=8&rft.spage=1317&rft.epage=1325&rft.pages=1317-1325&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s00277-018-3349-y&rft_dat=%3Cproquest_cross%3E2036910520%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2036910520&rft_id=info:pmid/29750316&rfr_iscdi=true |